文献速递贫血与红细胞疾病

静脉蔗糖铁治疗复发性缺铁性贫血的疗效与安全性

[The efficacy and safety of intravenous sucrose iron therapy for recurrent iron deficiency anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

回顾性分析2012年5月至2021年12月90例复发性缺铁性贫血患者,比较静脉铁剂组(60例)与口服铁剂组(30例)的疗效与安全性。静脉铁剂组在治疗后第4、8周血液学反应率、血红蛋白上升幅度及血清铁蛋白补充均显著优于口服铁剂组,不良反应发生率更低。

要点

  • 静脉铁剂组第4、8周血液学反应率分别为80.0%和96.7%,显著高于口服铁剂组的3.3%和46.7%。
  • 静脉铁剂组第4、8周血红蛋白中位增高38 g/L和44.5 g/L,显著高于口服铁剂组的7 g/L和19 g/L。
  • 静脉铁剂组不良反应发生率为3.3%,显著低于口服铁剂组的20.0%。

核心结论

  • 复发性缺铁性贫血患者应用静脉补铁较口服补铁血液学反应率更高,血红蛋白上升更快,储存铁补足率更高,患者耐受良好。

研究设计与样本

  • 回顾性分析2012年5月至2021年12月期间90例复发性缺铁性贫血患者的临床资料,比较静脉铁剂组与口服铁剂组的疗效及不良反应。

主要发现

  • 90例患者中男20例、女70例,中位年龄40(14,85)岁;60例接受静脉铁剂治疗,30例接受口服铁剂治疗。
  • 治疗后第4、8周静脉铁剂组血液学反应率分别为80.0%(48/60)、96.7%(58/60),显著高于口服铁剂组的3.3%(1/30)、46.7%(14/30)(Fisher,均P<0.001)。
  • 静脉铁剂组血红蛋白较基线第4、8周分别中位增高38(4,66)g/L和44.5(18,80)g/L,显著高于口服铁剂组的7(1,22)g/L和19(3,53)g/L(t=10.720,P<0.001;t=7.392,P<0.001)。
  • 静脉铁剂组血红蛋白恢复正常者分别为33例(55.0%)和54例(90.0%),显著高于口服铁剂组的0例和13例(43.3%)(Fisher,均P<0.001)。
  • 治疗后8周静脉铁剂组血清铁蛋白中位增高113.7(49.7,413.5)μg/L,53.8%(14/26)的患者血清铁蛋白≥100 μg/L,显著高于口服铁剂组的14.0(5.8,84.2)μg/L(t=4.760,P<0.001),口服铁剂组无血清铁蛋白≥100 μg/L患者(Fisher,P=0.013)。

关键数值与推荐

  • 静脉铁剂组不良反应发生率为3.3%(2/60),显著低于口服铁剂组的20.0%(6/30)(Fisher,P=0.015)。

临床怎么用

  • 复发性缺铁性贫血患者应用静脉补铁较口服补铁血液学反应率更高,血红蛋白上升更快,储存铁补足率更高,患者耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of intravenous iron supplementation in patients with recurrent iron deficiency anemia (IDA) . Methods: This retrospective analysis of 90 patients with recurrent IDA from May 2012 to December 2021 was conducted, comparing the efficacy and safety of the intravenous iron therapy group and the oral iron therapy group. Results: Among the 90 patients with recurrent IDA, 20 were males and 70 were females, with a median age of 40 (range: 14-85) years. A total of 60 patients received intravenous iron supplementation and 30 received oral iron supplementation. The hematologic response rates in the intravenous iron group were significantly higher than those in the oral iron group at 4 and 8 weeks after treatment [80.0% (48/60) vs 3.3% (1/30) and 96.7% (58/60) vs 46.7% (14/30), all P<0.001, respectively]. The median increase in hemoglobin levels was also significantly higher in the intravenous iron group than in the oral iron group [38 (4, 66) g/L vs 7 (1, 22) g/L at week 4 and 44.5 (18, 80) g/L vs 19 (3, 53) g/L at week 8, all P<0.001]. The intravenous iron group had a significantly higher proportion of patients who achieved normal hemoglobin levels than the oral iron group (55.0% vs 0 and 90% vs 43.3%, all P<0.001, respectively). Iron metabolism indicators were tested before and after 8 weeks of treatment in 26 and 7 patients in the intravenous and oral iron groups, respectively. The median increase in serum ferritin (SF) levels in the intravenous iron group 8 weeks after treatment was 113.7 (49.7, 413.5) μg/L, and 54% (14/26) of these patients had SF levels of ≥100 μg/L, which was significantly higher than the median increase in SF levels in the oral iron group [14.0 (5.8, 84.2) μg/L, t=4.760, P<0.001] and the proportion of patients with SF levels of ≥100 μg/L (P=0.013). The incidence of adverse reactions was 3.3% (2/60) in the intravenous iron group, which was significantly lower than that in the oral iron group [20.0% (6/30), P=0.015]. Conclusion: Intravenous iron supplementation is more effective for hematologic response, faster hemoglobin increase, and higher iron storage replenishment rates compared with oral iron supplementation in patients with recurrent IDA, and it is well tolerated by patients. 目的: 评估静脉铁剂治疗复发性缺铁性贫血(IDA)的有效性和安全性。 方法: 回顾性分析2012年5月至2021年12月期间90例复发性IDA患者的临床资料,比较静脉铁剂组与口服铁剂组的疗效及不良反应发生情况。 结果: 90例复发性IDA患者中,男20例,女70例,中位年龄40(14,85)岁。60例接受静脉铁剂治疗,30例接受口服铁剂治疗。补铁治疗后第4、8周,静脉铁剂组血液学反应率分别为80.0%(48/60)、96.7%(58/60),显著高于口服铁剂组患者的3.3%(1/30)、46.7%(14/30)(Fisher,均P<0.001);HGB较基线分别中位增高38(4,66)g/L和44.5(18,80)g/L,显著高于口服铁剂组的7(1,22)g/L和19(3,53)g/L(t=10.720,P<0.001;t=7.392,P<0.001);HGB恢复正常患者分别为33例(55.0%)和54例(90.0%),显著高于口服铁剂组的0例和13例(43.3%)(Fisher,均P<0.001)。静脉铁剂组和口服铁剂组分别有26例和7例在治疗前以及治疗后8周检测了铁代谢指标。治疗后8周静脉铁剂组血清铁蛋白(SF)中位增高值113.7(49.7,413.5)μg/L,53.8%(14/26)的患者血清SF≥100 μg/L,显著高于口服铁剂组的14.0(5.8,84.2)μg/L(t=4.760,P<0.001),而口服铁剂组则未有SF≥100 μg/L患者(Fisher,P=0.013)。静脉铁剂组不良反应率为3.3%(2/60),远低于口服铁剂组20.0%(6/30)(Fisher,P=0.015)。 结论: 复发性IDA应用静脉补铁较口服补铁治疗血液学反应率更高,HGB上升更快,储存铁补足率更高,患者耐受良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu JQ, Yang XW, Liu X, et al. [The efficacy and safety of intravenous sucrose iron therapy for recurrent iron deficiency anemia]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37550191. doi:10.3760/cma.j.issn.0253-2727.2023.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。